We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Researchers at China’s Shenzhen Institutes of Advanced Technology have found that pralatrexate, a chemotherapy drug used to treat lymphoma, may hold potential as a COVID-19 treatment and that it outperforms remdesivir in inhibiting the virus. Read More
Regeneron has released positive initial results from an ongoing phase 1/2/3 study evaluating its antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients who require low-flow oxygen. Read More
China announced that it has granted conditional authorization for one of Sinopharm’s inactivated COVID-19 vaccines, a shot that the state-owned pharma company claimed is 79.3 percent effective according to an interim analysis of its phase 3 trial. Questions remain, however, due to a lack of details from the company. Read More
“Our data clearly show that C21 can restore lung function on top of steroids and normalize gas exchange,” said Vicore CEO Carl-Johan Dalsgaard. Read More
Novavax has launched a phase 3 study in the U.S. and Mexico to evaluate its COVID-19 vaccine candidate, NVX-CoV2373, after deferring the trial for two months because of holdups in securing doses. Read More
The FDA rapped California-based drug manufacturer Sky Systems in a Form 483 with a dozen observations after an inspection revealed the firm lacked a quality control unit. Read More
In 2020, messenger RNA (mRNA), the technology behind Pfizer’s and Moderna’s COVID-19 vaccine, practically became a household word. Now the gate is open for more mRNA vaccines to flood the space. Read More
Swedish drugmaker Vicore Pharma has reported positive results from a phase 2 study evaluating its oral therapy for treating respiratory infection in hospitalized COVID-19 patients. Read More
AstraZeneca (AZ) and Amgen disclosed that their investigational asthma drug tezepelumab failed to achieve its primary endpoint of reducing dependence on oral corticosteroids while keeping asthma symptoms stable. Read More
The National Institutes of Health (NIH) has paused enrollment of critically ill COVID-19 patients in a phase 3 trial of various blood thinners, one of three international trials evaluating whether a full or lower dose of anticoagulants in hospitalized COVID-19 patients is more effective. Read More